EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access

Topical Preparations for Moderate to Severe Rosacea Treatment

Anissa Valentina Amstutz, Abizairie Sánchez-Feliciano, Eliza Dewey, Ursula Biba, Lana Salloum, John S Barbieri

JAMA Dermatology · 01.08.2026 · 162 (8) · 787

DOI: 10.1001/jamadermatol.2026.2062 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Dermatology, erschienen am 01.08.2026. Verfasst von Anissa Valentina Amstutz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Rosacea, Dermatologic Agents. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Comparative efficacy and tolerability of topical therapies for rosacea remain incompletely characterized, particularly for novel agents such as encapsulated benzoyl peroxide.

Objective

To compare the efficacy and tolerability of topical treatments for moderate to severe rosacea through a systematic review and network meta-analysis of randomized clinical trials (RCTs). Data Sources CENTRAL (Cochrane Central Register of Controlled Trials), MEDLINE via Ovid, Web of Science, and Embase databases were searched from inception through August 6, 2025, and supplemented by manual screening of references. Study Selection RCTs published in English that included adults with moderate to severe rosacea and assessed topical therapies for rosacea were included. Data Extraction and Synthesis Two reviewers independently extracted data and assessed risk of bias using the Cochrane Risk of Bias tool, version 2.0. Data were synthesized using random-effects network meta-analyses. Treatment rankings were estimated using SUCRA (surface under the cumulative ranking) values. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation framework. Main Outcomes and Measures Prespecified primary outcomes were mean change in absolute lesion count, Investigator Global Assessment (IGA) success, and discontinuation due to adverse events or effects. Secondary outcomes included patient-reported measures and clinician-assessed erythema.

Results

Of 2858 records screened, 32 RCTs met inclusion criteria, comprising a total of 11 399 adults treated with 10 topical interventions. Most studies had a 8- to 16-week follow-up period. Compared with metronidazole, ivermectin and encapsulated benzoyl peroxide demonstrated greater reductions in lesion count (mean difference [MD], 4.17; 95% CI, 1.85-6.48; and MD, 4.14; 95% CI, 0.62-7.66, respectively) and higher likelihood of IGA success (MD, 10.31; 95% CI, 2.85 to 17.77; and MD, 15.51; 95% CI, 2.35-28.68, respectively). Frequency of discontinuation due to adverse events were similar between treatments, although discontinuation was more frequent with encapsulated benzoyl peroxide than metronidazole (MD, 8.33; 95% CI, 0.45-16.22). Limited data precluded robust quantitative synthesis of patient-reported outcomes and erythema outcomes. Conclusions and Relevance In this systematic review and network meta-analysis, topical ivermectin and encapsulated benzoyl peroxide were more efficacious than metronidazole for rosacea, although encapsulated benzoyl peroxide was also associated with higher discontinuation due to adverse events. Future trials should evaluate long-term efficacy, tolerability, and standardized patient-reported outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RosaceaDermatologic AgentsHumansRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment OutcomeAdministration, CutaneousBenzoyl PeroxideMetronidazoleAdministration, Topical

Substanzen

Dermatologic AgentsBenzoyl PeroxideMetronidazole

Autor:innen und Institutionen

  • Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Associate Editor, JAMA Dermatology.

Zitieren

APA

Amstutz, A. V., Sánchez-Feliciano, A., Dewey, E., Biba, U., Salloum, L., & Barbieri, J. S. (2026). Topical Preparations for Moderate to Severe Rosacea Treatment. JAMA Dermatology, 162(8), 787. https://doi.org/10.1001/jamadermatol.2026.2062

Vancouver

Amstutz AV, Sánchez-Feliciano A, Dewey E, Biba U, Salloum L, Barbieri JS. Topical Preparations for Moderate to Severe Rosacea Treatment. JAMA Dermatology. 2026;162(8):787. doi:10.1001/jamadermatol.2026.2062

BibTeX
@article{Amstutz2026,
  author = {Amstutz, Anissa Valentina and Sánchez-Feliciano, Abizairie and Dewey, Eliza and Biba, Ursula and Salloum, Lana and Barbieri, John S},
  title = {Topical Preparations for Moderate to Severe Rosacea Treatment},
  journal = {JAMA Dermatology},
  year = {2026},
  volume = {162},
  number = {8},
  pages = {787},
  doi = {10.1001/jamadermatol.2026.2062}
}
Kostenlos starten →